
Explore our Novel Drug Pipeline
Quantum X is a parent company to MAA Global consisting of leading scientists, where we develop novel therapeutics and much more
Learn more about novel drug licensing , as well as research and development services to excel in medicinal invention, learn more about our current projects such as HLADrvax, a novel vaccine and breakthrough for Rheumatoid Arthritis.
Whats HLADrvax?
At Quantum X, we are redefining the future of autoimmune care with HLADrvax—a novel therapeutic solution designed to both treat early-stage Rheumatoid Arthritis (RA) and potentially prevent its onset.
Currently in the research and development phase, HLADrvax leverages advanced biochemical and biological methodologies to address a critical unmet need in immunosuppressive disease treatment. Our innovative approach targets immune system regulation at its core, offering hope for millions affected by RA.
With HLADrvax, Quantum X is committed to closing the gap in autoimmune therapeutics—driving progress, promoting prevention, and improving lives. HLADrvax has surpassed successful preclinical trials- paving way for successful treatment approaches to deadly disease.
Innovative Therapeutics, Breakthrough Treatments
Innovative Therapeutics, Breakthrough Treatments
NeuroVax-MS™ is a precision immunotherapy for multiple sclerosis that aims to selectively recalibrate pathogenic immune responses while preserving protective immunity. It is built on a proprietary platform that enables specific modulation of autoreactive pathways implicated in demyelination.

LupraMod™ is a novel therapy addressing the complexity of lupus by rebalancing immune hyperactivity and restoring tolerance mechanisms. Unlike broad immunosuppressants, LupraMod™ offers a more targeted approach to reduce flares and organ damage while minimizing infection risk.
:
MetaboVax™ is a novel therapeutic designed to address obesity at its biological root by modulating appetite and energy regulation pathways. Its unique mechanism aims to provide durable weight management without the cardiovascular and gastrointestinal safety concerns of current agents.
